Kristin Yarema - Jan 2, 2024 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
President and CEO, Director
Signature
/s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:03 PM
Previous filing
Apr 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +250K +70.06% $0.00 607K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to buy) Award $0 +345K $0.00 345K Jan 2, 2024 Common Stock 345K $3.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments beginning from the first anniversary of January 1, 2024.
F2 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 42 equal monthly installments thereafter.